Is Rafael Holdings, Inc. (RFL) Halal?
Shariah Screening — 5 Standards
Based on financial data from July 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.1% / 30% | 85.5% / 30% | 8.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 3.1% / 33% | 85.5% / 33% | 8.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.5% / 33% | 68.1% / 33% | 6.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 3.1% / 33% | 85.5% / 33% | 8.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.5% / 33% | 68.1% / 33% | 6.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 93.1% | |
| Operating Margin | -3154.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -41.4% | |
| Return on Assets (ROA) | -23.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $2M |
| Debt-to-Equity | 0.8 |
| Current Ratio | 3.4 |
| Total Assets | $97M |
Price & Trading
| Last Close | $1.26 |
| 50-Day MA | $1.27 |
| 200-Day MA | $1.45 |
| Avg Volume | 95K |
| Beta | 0.5 |
|
52-Week Range
$1.12
| |
About Rafael Holdings, Inc. (RFL)
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Related Halal Stocks in Real Estate
Frequently Asked Questions
Is Rafael Holdings, Inc. (RFL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Rafael Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Rafael Holdings, Inc.'s debt ratio?
Rafael Holdings, Inc.'s debt ratio is 3.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.5%.
What are Rafael Holdings, Inc.'s key financial metrics?
Rafael Holdings, Inc. has a market capitalization of $65M. Return on equity stands at -41.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.